The results of the Swedish two-county study are analysed with respect to tumour size, nodal status and malignancy grade, and the relationship of these prognostic factors to screening and to survival. It is shown that these factors can account for much of the differences in survival between incidence screen detected, interval and control group cancers but to a lesser extent for cancers detected at the prevalence screen where length bias is greatest. Furthermore, examination of the relationships among the prognostic factors and mode of detection indicates that malignancy grade, as a measure of inherent malignant capacity, evolves as a tumour grows. The proportion of cancers with poor malignancy grade is several fold lower for cancers of diameter less than 15 cm than for cancers greater than 30 cm, independent of the length bias of screening. The implications of these findings for screening frequency are briefly discussed.
It has been shown that mortality from breast cancer can be reduced by mass screening using mammography (Shapiro et al., 1982; Tabar et al., 1985) , a reduction resulting from earlier diagnosis. The natural history of breast cancer, however, is clearly heterogeneous, with substantial variation among tumours in their malignant potential, rate of growth and prognosis. Further, little is known of the rate at which prognosis deteriorates as a tumour develops or conversely how prognosis improves as the time of diagnosis is advanced.
It is known that screening does reduce rates of larger tumours and of metastases Tabar et al., 1987) . Moreover, these factors affect survival, as does malignancy grades. However, these relationships have not been fully quantified in a screening context, so the mechanism whereby screening can reduce mortality is not fully understood. The purpose of the present paper is to examine, using the results of the Swedish two-county study:
(1) the relationships among the prognostic factors: tumour size, nodal involvement and malignancy grade; (2) the change in these factors brought about by screening; (3) the extent to which the change in the distributions of prognostic factors achieved by screening can account for the mortality reduction; (4) whether malignancy grade is affected by an advance in the time of diagnosis or whether it is an inherent characteristic; and (5) whether the prognostic variables listed above, or a subset of them, can be used as surrogate variables for the final endpoint, breast cancer mortality, i.e. can future mortality be accurately predicted using these variables, for screened and unscreened populations?
Subjects and methods
The data is from the Swedish two-county trial of mammographic screening for breast cancer, and is confined to women aged 40-69 at entry, among whom compliance was good. In this age group, 66,741 women were invited to regular mammographic screening and 48,678 women were not (Tabar et al., 1989) . Principal results and further details of the trial are given elsewhere (Tabar et al., 1985 (Bloom & Richardson, 1957; Scarff & Torloni, 1968) was determined by one pathologist in each county, but as results demonstrate, there were differences between the two counties in proportions of grades 1, 2 and 3, probably reflecting subjectivity in classification of tumour grade rather than a difference in the two tumour populations. No such differences were observed between counties for tumour size or node status.
Statistical analysis of associations among tumour characteristics was performed using log-linear modelling and logistic regression (Aitkin et al., 1989) . These methods yield likelihood ratio (deviance) chi-squared tests for significance of associations and odds ratio estimates of relative risks (for example of being nodes positive for given grade relative to grade 1). Survival analysis was performed using proportional hazards regression (Cox, 1972 
Results
The relationship between size, nodal status, malignancy grade and detection mode Table I presents the univariate distribution for the three prognostic variables, by mode of detection and for malignancy grade by county. The malignancy grade distribution clearly varies by county. All three prognostic variables, as expected, are significantly related to detection mode, being more favourable among screen detected cancers; cancers among refusers tend to have poor malignancy grade, to be very large and to have distant metastases.
The relationship between the three prognostic variables has been examined in two ways. First, we have considered the proportion of cancers with positive nodes in relation to the size and malignancy grade of the primary tumours, i.e. the probability of dissemination as determined by the characteristics of the primary tumour. Table Ila and Ilb crosstabulate the proportion node positive with size and grade; a strong relationship with both is evident. Grade and size are also closely related (Table III) , so a logistic regression was performed of proportion node positive against size, grade, age, dectection mode and county as shown in Table IV . The major factor is clearly tumour size, athough there was a moderate significant residual effect of grade. Detection mode remained significant, with an appreciably lower proportion of node positive cancers among the screen detected, particularly cancers detected at later screens. Interval and control group cancers performed similarly. There was no indication that the relative effect of malignancy grade on dissemination varied with the size of the tumour.
The second way in which the interrelationships of the prognostic factors has been examined is in terms of the primary tumour itself, the relationship between size and malignancy. The proportion with the worst malignancy grade (grade 3 tumour) was regressed (logistic regression) against size, detection mode, age and county, as shown in Table Va . Size again is the overwhelmingly dominant factor. There is some residual effect, however, of detection mode, with interval cancers and especially cancers in the refusers displaying a higher proportion of poor grade cancers than would be predicted on the basis of size. The poor grade of interval cancers occurs mainly in cancers less than 2 cm in diameter, Significance of difference between observed and expected, P = 0.7. (Ponten et al., 1990) . They conclude that the evidence is against it occurring, citing results that DNA ploidy is similar in (incidence) screen detected as in clinically detected cancers, even though the former are diagnosed on average some 3 years earlier.
On the other hand, giving support to the possibility that the malignant capacity of a cancer may evolve are recent results demonstrating that many cancers display considerable heterogeneity in terms of thymidine labelling index (TLI) and steroid hormone receptors, and a lower degree of within tumour heterogeneity for DNA ploidy (Meyer & Wittliff, 1991) . Heterogeneity provides a potential for differential growth rates of different cell populations in a tumour. The situation would be greatly clarified if biochemical or genetic measures of malignancy could be developed, demonstrably related to survival and accounting for the effects of the subjective measure of malignancy grade, and for which evidence analogous to Table VI could be adduced.
The implications for breast screening if malignancy evolves with tumour growth are important. It would suggest that the benefit from screening comes not only from the smaller size at which cancers are detected, but also from an overall reduction in the degree of malignancy. Screening more frequently would, then, in addition to reducing the number of interval cancers, improve appreciably the prognostic characteristics of the screen detected cancers.
It is interesting to note that much of the effect of size, both its independent effect on survival and its relationship with tumour grade, is absent if one considers only tumours greater than 2 cm in diameter, that is, cancers which are generally detectable clinically. Most of the size effect occurs in the difference between these tumours and those smaller than 2 cms in diameter, when detection by mammography is of greatest relevance. In clinically detected cancers one would not expect to observe a major independent effect for size on either survival (Haybittle et al., 1982) or on malignancy grade.
Screening women over 50 years of age every 33 months reduces breast cancer mortality by some 40% (over a 10-year period, for the women screened). The results of this paper suggest that more frequent screening may yield substantially improved benefits.
